^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
Excerpt:
...Cancer tissue pathology is clearly HER2 positive: including IHC2+/ISH+, IHC 3+ or HER2 mutations (the results obtained by NGS method, PCR method, Sanger method, mass spectrometry sequencing and other measurement methods are all acceptable)....
Trial ID:
Source:
Title:
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Excerpt:
...Patients with HER2 positive (defined as documented overexpression or amplification or mutation) metastatic breast cancer who have experienced disease progression following at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required; 2....
Trial ID:
More C2 evidence
Source:
Title:
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Excerpt:
...- Histologically or cytologic confirmed HER2 positive advanced Non-small cell lung cancer who failed prior therapies....
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis
Published date:
11/24/2021
Excerpt:
A total of 32 trials involving 958 patients were included. The ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment, and antibody-drug conjugate (ADC) (T-DM1) were 22% (95% CI 11-31), 23% (95% CI 20-65), 26% (95% CI 14-39), and 16% (95% CI -6-37), while that of ADC (DS-8201) was 60% (95% CI 35-85)....In particular, ADC (DS-8201), pyrotinib, and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC.
DOI:
10.1111/bcp.15155
